Estudo randomizado | Daratumumabe, lenalidomida e dexametasona vs. lenalidomida e dexametasona isoladas no tratamento do mieloma múltiplo recém-diagnosticado.

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial – The Lancet Oncology

Comentário: Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma – The ASCO Post